Treatment in metastatic melanoma-time to re-think

Affiliations

¹ Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: dirk.schadendorf@uk-essen.de.
² Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Heidelberg, Germany.

Free article

Editorial

D Schadendorf et al. Ann Oncol. 2019.

Free article

. 2019 Apr 1;30(4):501-503.

doi: 10.1093/annonc/mdz050.

¹ Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: dirk.schadendorf@uk-essen.de.
² Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Heidelberg, Germany.

No abstract available

Comment on

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A. Hamid O, et al. Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011. Ann Oncol. 2019. PMID: 30715153 Free PMC article. Clinical Trial.